New Once-Daily pill aims to lower high triglycerides
NCT ID NCT04716595
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new extended-release form of pemafibrate (K-877) in 121 adults with high triglycerides, a type of fat in the blood. Participants took the drug once daily for 52 weeks, either in the morning or evening, to see if it safely lowers triglyceride levels and improves cholesterol. The goal is to offer a convenient treatment option for managing dyslipidemia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pemafibrate (K-877) extended-release tablet
What this could lead to
If successful, this could provide a once-daily treatment option to lower high triglycerides and improve cholesterol levels, helping manage heart disease risk.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The drug may not work better than existing treatments, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Akasaka Chuou Clinic
Tokyo, Japan
-
Cosmos medical corporation Aozora total clinic
Saitama, Japan
-
Hasegawa Medicine Clinic
Hokkaido, Japan
-
Japan Community Health care Organization Hokkaido Hospital
Hokkaido, Japan
-
Kinugawa Cardiology Clinic
Osaka, Japan
-
Kyosokai AMC NISHI-UMEDA Clinic
Osaka, Japan
-
Medical Corporation Chiseikai Tokyo Center Clinic
Tokyo, Japan
-
Medical corporation Tani clinic
Osaka, Japan
-
Minami Akatsuka Clinic
Ibaraki, Japan
-
National Hospital Organization Takasaki General Medical Center
Gunma, Japan
-
Saiseikai Futsukaichi Hospital
Fukuoka, Japan
-
Saiseikai Yokohamashi Nanbu Hospital
Kanagawa, Japan
-
Shimokitazawa Tomo Clinic
Tokyo, Japan
-
Shiraiwa medical clinic
Osaka, Japan